Overview

X-82 to Treat Age-related Macular Degeneration

Status:
Terminated
Trial end date:
2018-01-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.
Phase:
Phase 2
Details
Lead Sponsor:
Tyrogenex
Collaborators:
International Drug Development Institute
SynteractHCR, Inc
Treatments:
Aflibercept
Bevacizumab
Ranibizumab